Piramal Pharma quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	2,617	2,044	+28.1%
EBITDA	349	159	+119.8%
EBITDA margin	13.3%	7.8%	+5.6 pts
Profit before tax	63.9	−61.0	—
Net profit	5.0	−99.2	—
EPS	₹0.04	−₹0.75	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	2,617	2,270	2,752	2,140	2,044	1,934	2,754	2,204	2,242	1,951	2,552	1,959	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	35.9	89.4	46.1	43.2	65.6	58.4	42.0	12.1	61.1	19.5	26.4	61.5
	2,653	2,359	2,798	2,183	2,109	1,992	2,796	2,216	2,303	1,971	2,579	2,020
	646	725	483	505	483	524	204	805	575	471	400	628
	335	420	336	377	375	343	547	161	395	315	436	228
	−75.0	−293	237	−96.0	−156	−173	205	−161	−173	−112	178	−180
	714	676	586	600	611	619	612	556	560	580	494	524
	87.6	88.1	83.0	89.2	82.4	86.2	104	103	108	107	114	106
	233	224	218	213	203	197	243	197	192	185	196	186
	648	547	650	558	571	514	626	504	544	493	514	491
	2,589	2,386	2,593	2,246	2,170	2,110	2,540	2,167	2,200	2,038	2,333	1,982
	349	195	461	196	159	107	561	338	342	204	530	268
	116	−28.4	242	−17.0	−44.2	−90.6	318	141	149	19.9	334	82.1
Profit
	63.9	−27.0	205	−63.0	−61.0	−118	257	49.8	103	−67.5	246	37.7
	0.0	0.0	−176	−41.1	0.0	20.7	0.0	0.0	0.0	0.0	−30.5	−32.3
	63.9	−27.0	29.4	−104	−61.0	−97.6	257	49.8	103	−67.5	215	5.4
	72.2	65.4	25.7	46.9	55.3	34.2	93.8	72.0	94.3	50.1	101	33.4
	4.4	−3.4	26.1	−4.5	−2.3	−31.5	25.5	−8.9	3.3	−6.5	25.3	−24.1
	76.6	61.9	51.8	42.3	53.0	2.7	119	63.1	97.5	43.6	126	9.3
	17.7	19.6	13.6	10.3	14.8	18.6	16.2	17.1	17.3	22.4	12.0	14.0
	5.0	−69.4	−8.8	−136	−99.2	−81.7	154	3.7	22.6	−88.6	101	10.1
	−12.7	−89.0	−22.4	−146	−114	−100	137	−13.4	5.3	−111	89.2	−3.8
	43.8	−30.6	163	60.1	70.9	44.1	14.0	15.1	55.0	−4.2	−22.2	43.8
	48.8	−99.9	154	−76.1	−28.3	−37.6	167	18.8	77.6	−92.8	79.1	53.9
	5.6	−69.4	−8.8	−136	−99.2	−81.7	154	3.7	22.6	−88.6	—	—
	−0.6	0.0	0.0	0.0	—	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Per share
	₹0.04	−₹0.52	−₹0.07	−₹1.03	−₹0.75	−₹0.62	₹1.16	₹0.03	₹0.17	−₹0.67	₹0.77	₹0.08
	₹0.04	−₹0.52	−₹0.07	−₹1.03	−₹0.75	−₹0.62	₹1.16	₹0.03	₹0.17	−₹0.67	₹0.77	₹0.08
Other comprehensive income — detail
	43.8	−30.6	163	60.1	70.9	44.1	14.0	—	—	—	—	—
	−4.4	−9.8	−10.2	2.4	0.1	−4.9	−1.7	−1.1	−0.0	−5.5	0.9	0.2
	−1.1	−2.5	−2.6	0.6	0.0	−1.2	−0.4	—	—	—	—	—
	—	—	—	—	—	—	—	−0.3	−0.0	−1.4	0.2	0.0
	52.5	−23.1	190	61.5	73.8	66.0	27.1	5.4	57.4	0.1	−23.0	45.2
	5.4	0.1	18.7	3.2	3.0	18.2	11.9	—	—	—	—	—
	—	—	—	—	—	—	—	−10.4	2.4	0.2	−0.1	1.4
	49.4	−99.9	154	−76.1	−28.3	−37.6	—	18.8	77.6	−92.8	79.1	53.9
	−0.6	0.0	0.0	0.0	—	0.0	—	0.0	0.0	0.0	0.0	0.0
Per share — as-filed variants
	₹0.04	−₹0.52	−₹0.07	−₹1.03	−₹0.75	−₹0.62	₹1.16	₹0.03	₹0.17	−₹0.67	₹0.77	₹0.08
	₹0.04	−₹0.52	−₹0.07	−₹1.03	−₹0.75	−₹0.62	₹1.16	₹0.03	₹0.17	−₹0.67	₹0.77	₹0.08
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,711	1,418	1,696	1,354	1,341	1,240	1,799	1,398	1,445	1,277	1,538	1,283
	65.4%	62.5%	61.6%	63.3%	65.6%	64.1%	65.3%	63.4%	64.5%	65.4%	60.3%	65.5%
Adjusted (ex-exceptional items) — derived
	63.9	−27.0	205	−63.0	−61.0	−118	257	49.8	103	−67.5	246	37.7
	0.0	0.0	−176	−41.1	0.0	20.7	0.0	0.0	0.0	0.0	−30.5	−32.3
	5.0	−69.4	61.5	−95.1	−99.2	−102	154	3.7	22.6	−88.6	114	23.0
	₹0.04	−₹0.52	₹0.49	−₹0.72	−₹0.75	−₹0.78	₹1.16	₹0.03	₹0.17	−₹0.67	₹0.87	₹0.18

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PPLPHARMA₹230.78

Piramal Pharma Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersDIVISLAB SYNGENE GLAND WOCKPHARMA ASTERDM COHANCE LALPATHLAB NATCOPHARMMcap ₹30,628 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	1,958.6	2,552.4	1,951.1	2,241.8	2,204.2	2,754.1	1,933.7	2,043.7	2,139.9	2,751.8	2,269.9	2,617.1
Other Income	61.5	26.4	19.5	61.1	12.1	42.0	58.4	65.6	43.2	46.1	89.4	35.9
Total Income	2,020.1	2,578.7	1,970.7	2,302.9	2,216.4	2,796.1	1,992.1	2,109.3	2,183.1	2,797.8	2,359.3	2,653.0
Expenses
+ Cost of Materials Consumed	627.6	400.1	471.5	575.1	805.4	203.7	524.4	483.4	505.5	482.6	724.8	645.8
+ Purchases of Stock-in-Trade	227.9	436.1	314.8	394.8	161.1	546.7	342.8	374.8	376.8	336.0	420.2	335.4
+ Changes in Inventories	-180.4	178.3	-111.9	-173.4	-160.7	204.6	-173.1	-155.8	-96.0	237.1	-292.7	-75.0
+ Employee Benefit Expense	523.8	494.2	579.7	559.5	556.2	612.0	618.6	611.5	599.9	586.0	675.6	714.3
+ Finance Costs	105.9	114.2	107.0	107.6	103.3	103.7	86.2	82.4	89.2	83.0	88.1	87.6
+ Depreciation & Amortisation	186.3	196.1	184.6	192.2	196.8	242.8	197.3	202.8	212.7	218.4	223.6	233.2
+ Other Expenses	491.3	513.9	492.6	544.1	504.4	626.1	514.4	571.1	558.0	649.6	546.8	647.8
Total Expenses	1,982.4	2,332.8	2,038.2	2,200.0	2,166.6	2,539.5	2,110.4	2,170.3	2,246.1	2,592.6	2,386.4	2,589.1
EBITDA	268.4	529.9	204.5	341.6	337.7	561.0	106.7	158.7	195.7	460.5	195.2	348.7
EBIT	82.1	333.8	19.9	149.4	140.9	318.2	-90.6	-44.2	-17.0	242.1	-28.4	115.6
Profit
PBT before Exceptional Items	37.7	246.0	-67.5	102.9	49.8	256.6	-118.3	-61.0	-63.0	205.2	-27.0	63.9
+ Exceptional Items	-32.3	-30.5	0.0	0.0	0.0	0.0	20.7	0.0	-41.1	-175.8	0.0	0.0
Pretax Income	5.4	215.4	-67.5	102.9	49.8	256.6	-97.6	-61.0	-104.1	29.4	-27.0	63.9
+ Current Tax	33.4	100.9	50.1	94.3	72.0	93.8	34.2	55.3	46.9	25.7	65.4	72.2
+ Deferred Tax	-24.1	25.3	-6.5	3.3	-8.9	25.5	-31.5	-2.3	-4.5	26.1	-3.4	4.4
Tax Expense	9.3	126.2	43.6	97.5	63.1	119.3	2.7	53.0	42.3	51.8	61.9	76.6
+ Share of Associates & JVs	14.0	12.0	22.4	17.3	17.1	16.2	18.6	14.8	10.3	13.6	19.6	17.7
Net Income	10.1	101.3	-88.6	22.6	3.7	153.5	-81.7	-99.2	-136.2	-8.8	-69.4	5.0
+ Net Income — Continuing Ops	-3.8	89.2	-111.0	5.3	-13.4	137.3	-100.3	-114.0	-146.5	-22.4	-89.0	-12.7
+ Other Comprehensive Income	43.8	-22.2	-4.2	55.0	15.1	14.0	44.1	70.9	60.1	163.3	-30.6	43.8
Total Comprehensive Income	53.9	79.1	-92.8	77.6	18.8	167.5	-37.6	-28.3	-76.1	154.5	-99.9	48.8
Net Income to Common	—	—	-88.6	22.6	3.7	153.5	-81.7	-99.2	-136.2	-8.8	-69.4	5.6
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	—	0.0	0.0	0.0	-0.6
Per Share
Basic EPS	0.08	0.77	-0.67	0.17	0.03	1.16	-0.62	-0.75	-1.03	-0.07	-0.52	0.04
Diluted EPS	0.08	0.77	-0.67	0.17	0.03	1.16	-0.62	-0.75	-1.03	-0.07	-0.52	0.04
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	14.0	44.1	70.9	60.1	163.3	-30.6	43.8
+ Items NOT to be Reclassified to P&L	0.2	0.9	-5.5	-0.0	-1.1	-1.7	-4.9	0.1	2.4	-10.2	-9.8	-4.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	-0.4	-1.2	0.0	0.6	-2.6	-2.5	-1.1
+ Tax on Items NOT to be Reclassified — alt tag	0.0	0.2	-1.4	-0.0	-0.3	—	—	—	—	—	—	—
+ Items to be Reclassified to P&L	45.2	-23.0	0.1	57.4	5.4	27.1	66.0	73.8	61.5	189.6	-23.1	52.5
+ Tax on Items to be Reclassified	—	—	—	—	—	11.9	18.2	3.0	3.2	18.7	0.1	5.4
+ Tax on Items to be Reclassified — alt tag	1.4	-0.1	0.2	2.4	-10.4	—	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	53.9	79.1	-92.8	77.6	18.8	—	-37.6	-28.3	-76.1	154.5	-99.9	49.4
Comprehensive Income — Non-controlling Interests	0.0	0.0	0.0	0.0	0.0	—	0.0	—	0.0	0.0	0.0	-0.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.08	0.77	-0.67	0.17	0.03	1.16	-0.62	-0.75	-1.03	-0.07	-0.52	0.04
Diluted EPS — Continuing Operations	0.08	0.77	-0.67	0.17	0.03	1.16	-0.62	-0.75	-1.03	-0.07	-0.52	0.04
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,283.4	1,538.0	1,276.8	1,445.3	1,398.4	1,799.1	1,239.7	1,341.2	1,353.6	1,696.1	1,417.7	1,710.9
Gross Margin %	65.53	60.26	65.44	64.47	63.44	65.32	64.11	65.63	63.25	61.64	62.45	65.37
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	37.7	246.0	-67.5	102.9	49.8	256.6	-118.3	-61.0	-63.0	205.2	-27.0	63.9
− Exceptional Items (reconciliation)	-32.3	-30.5	0.0	0.0	0.0	0.0	20.7	0.0	-41.1	-175.8	0.0	0.0
Net Income Adj (tax-effected)	23.0	113.9	-88.6	22.6	3.7	153.5	-102.4	-99.2	-95.1	61.5	-69.4	5.0
EPS Adj	0.18	0.87	-0.67	0.17	0.03	1.16	-0.78	-0.75	-0.72	0.49	-0.52	0.04
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	1,323.0	1,323.0	1,323.0	1,323.1	1,323.6	1,324.4	1,324.8	1,325.5	1,325.8	1,327.2	1,327.4	1,328.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Piramal Pharma Q2 FY27 results (July–September 2026)

Filed with NSE on Tuesday, 27 October 2026 at 9:02 pm IST

Piramal Pharma (NSE: PPLPHARMA) reported its Q2 FY27 results (July–September 2026) on Tuesday, 27 October 2026 at 9:02 pm IST. Consolidated net profit attributable to shareholders was ₹5.6 crore, against a loss of ₹99.2 crore in Q2 FY26 and against a loss of ₹69.4 crore in Q1 FY27. Revenue from operations was ₹2,617 crore, up 28.1% year on year and up 15.3% from the previous quarter.

Q2 FY26 results (a year earlier): 5 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit (shareholders'): ₹5.6 Crloss ₹99.2 Cr in Q2 FY26loss ₹69.4 Cr in Q1 FY27Total incl. minority interest ₹5 Cr
Revenue from operations: ₹2,617 Cr+28.1% vs Q2 FY26+15.3% vs Q1 FY27
Operating margin (EBIT): 4.4%+6.6 pts vs Q2 FY26+5.7 pts vs Q1 FY27EBIT ₹116 Cr
EBITDA: ₹349 Cr+119.8% vs Q2 FY26+78.7% vs Q1 FY27margin 13.3%
Earnings per share (basic): ₹0.04
Net profit margin: 0.2%+5.1 pts vs Q2 FY26+3.3 pts vs Q1 FY27

Questions

What was Piramal Pharma's net profit in Q2 FY27?

Consolidated net profit attributable to shareholders was ₹5.6 crore, against a loss of ₹99.2 crore in Q2 FY26 and against a loss of ₹69.4 crore in Q1 FY27. Including the minority shareholders' share, total profit was ₹5 crore.

What was Piramal Pharma's operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹116 crore, a margin of 4.4%, against −1.2% in Q1 FY27 and −2.2% in Q2 FY26. EBITDA was ₹349 crore, 13.3% of revenue.

What was Piramal Pharma's net profit in the first half of FY27?

Consolidated net loss attributable to shareholders for the first half of FY27 (April–September 2026) was ₹63.8 crore, narrower than the loss of ₹181 crore in the same months a year earlier. Revenue from operations was ₹4,887 crore, up 22.9%.

What was Piramal Pharma's revenue in Q2 FY27?

Revenue from operations was ₹2,617 crore, up 28.1% year on year and up 15.3% from the previous quarter.

How were Piramal Pharma's Q2 FY27 results?

A net profit of ₹5.6 crore, against a loss of ₹99.2 crore in Q2 FY26. Revenue was up 28.1% at ₹2,617 crore. The operating margin was 4.4%, up 6.6 percentage points from −2.2% a year earlier.

What was Piramal Pharma's EPS in Q2 FY27?

Basic earnings per share were ₹0.04.

What is Piramal Pharma's net profit margin?

Piramal Pharma's net profit margin was 0.2% in Q2 FY27 (net profit attributable to shareholders as a share of revenue from operations), against −4.9% in Q2 FY26 (up 5.1 percentage points). For FY26 as a whole it was −3.7%.

What was Piramal Pharma's net profit in FY26?

Consolidated net profit attributable to shareholders was a loss of ₹326 crore in FY26 (April 2025–March 2026), against a profit of ₹91.1 crore in FY25. It was a profit of ₹17.8 crore in FY24 and a loss of ₹186 crore in FY23.

What was Piramal Pharma's revenue in FY26?

Revenue from operations was ₹8,869 crore in FY26 (April 2025–March 2026), down 3.1% from ₹9,151 crore in FY25. It was ₹8,171 crore in FY24 and ₹7,082 crore in FY23: up 25.2% over three years, 7.8% a year on average.

How has Piramal Pharma's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: a loss of ₹136 crore in Q3 FY26, a loss of ₹8.8 crore in Q4 FY26, a loss of ₹69.4 crore in Q1 FY27 and a profit of ₹5.6 crore in Q2 FY27. That is a combined loss of ₹209 crore over the four quarters. Revenue from operations: ₹2,140 crore, ₹2,752 crore, ₹2,270 crore and ₹2,617 crore.

When did Piramal Pharma announce its Q2 FY27 results?

On Tuesday, 27 October 2026 at 9:02 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 5 November 2025.

When will Piramal Pharma announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Piramal Pharma figures come from?

From Piramal Pharma's own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 27 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.